BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates
BridgeBio Pharma, Inc. (BBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates - $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians i
How this was made
The 30-second read
Why it matters
The most tradable elements are the newly disclosed FDA review milestones (Priority Review acceptances and PDUFA dates) alongside cash runway and quarterly revenue composition, which together affect probability-weighted valuation into late-2026 catalysts.
Market read
Traders get a combined package of quarterly financials, cash position, and concrete FDA timeline catalysts for BBIO’s three near-term regulatory events.
What to watch
The filing emphasizes RWE and post-hoc analyses; investors may discount these versus prospective endpoints, and the market may scrutinize whether launch execution assumptions match payer adoption and pricing.
BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates
BridgeBio reported $243.7 million in total revenues, net, primarily from $222.4 million of U.S. Attruby net product revenue, while advancing all three planned NDA programs into regulatory review and adding $1 billion of preferred equity financing after quarter end.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenues, netother | $243.7M | – | – |
| U.S. Attruby net product revenueother | $222.4M | – | – |
| Royalty revenueother | $15.4M | – | – |
| License and services revenueother | $5.8M | – | – |
| Cash, cash equivalents, and marketable securitiesother | $720.2M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| U.S. Attruby net product revenueGrowth was led by the treatment-naïve segment as physicians increasingly start and keep patients on Attruby. | $222.4M | – | – |
| Royalty revenueNo driver was quantified in the provided filing text. | $15.4M | – | – |
| License and services revenueNo driver was quantified in the provided filing text. | $5.8M | – | – |
What drove it
- Second quarter revenue was primarily comprised of U.S. Attruby net product revenue.
- Attruby growth was led by the treatment-naïve segment.
- BBP-418 for LGMD2I/R9 was accepted with Priority Review, with a PDUFA target action date of November 27, 2026.
- Encaleret for ADH1 was accepted with Priority Review, with a PDUFA target action date of May 8, 2027.
- Oral infigratinib for achondroplasia has been submitted to the FDA, with U.S. launch expected mid-2027.
- BridgeBio stated that all three planned NDAs are now submitted to the FDA.
Concerns
- The provided filing text does not include GAAP or non-GAAP profitability, margin, expense, cash-flow, debt, or per-share results.
- Total revenues, net were primarily comprised of U.S. Attruby net product revenue.
- The planned launches of BBP-418 and encaleret remain contingent on FDA approval, and oral infigratinib remains under FDA review.
- BridgeBio stated that promotional activity for BBP-418 will commence only upon FDA approval.
What to watch
- PDUFA target action date of November 27, 2026 for BBP-418 for LGMD2I/R9.
- PDUFA target action date of May 8, 2027 for encaleret for ADH1.
- FDA setting a PDUFA date for oral infigratinib for achondroplasia.
- Phase 2 clinical trial update for oral infigratinib in hypochondroplasia expected in the second half of 2026.
- First participant dosed in RECLAIM-HP in the third quarter of 2026.
- BridgeBio Commercial Day in New York City on October 8, 2026.
Balance sheet and cash flow
- $720.2 million in cash, cash equivalents, and marketable securities as of June 30, 2026.
- The $720.2 million balance did not include the $1 billion preferred equity financing that closed on July 1, 2026.
Analysis
BridgeBio reported $243.7 million in total revenues, net, in the second quarter ended June 30, 2026. The revenue base was primarily commercial, with $222.4 million of U.S. Attruby net product revenue, alongside $15.4 million of royalty revenue and $5.8 million of license and services revenue. Management attributed Attruby growth to the treatment-naïve segment as physicians increasingly start and keep patients on the product.
The commercial update was paired with additional clinical and real-world evidence for Attruby. Post-hoc analyses reported a placebo-corrected 15.5% reduction in urinary albumin-to-creatinine ratio by Day 28, a sustained improvement in chronic eGFR slope of +2.47 mL/min/1.73m²/year, and a 13.7% UACR reduction through Month 30. BridgeBio also cited independent real-world analyses associating acoramidis with a 37% reduction in composite cardiovascular events and a 34% reduction in hospitalizations at six months versus tafamidis.
The pipeline advanced materially during the period, with all three planned NDAs submitted to the FDA. BBP-418 received Priority Review with a November 27, 2026 PDUFA target action date, while encaleret received Priority Review with a May 8, 2027 PDUFA target action date. Oral infigratinib for achondroplasia has been submitted to the FDA, and the company stated that U.S. launch is expected mid-2027. These programs create a concentrated regulatory and launch execution agenda across multiple rare-disease indications.
Liquidity was $720.2 million in cash, cash equivalents, and marketable securities as of June 30, 2026. That balance excludes the $1 billion preferred equity financing that closed on July 1, 2026, which management said sizes the balance sheet to run all three launches at full strength without diverting resources from the development engine. The provided text contains no operating expense, net income, EPS, cash-flow, debt, margin, or formal financial guidance figures, limiting assessment of earnings quality, cash consumption, and the cost of upcoming launch investments.
Investor attention should center on continued Attruby commercial execution, the upcoming BBP-418 PDUFA date, the encaleret review timetable, and FDA timing for oral infigratinib. BridgeBio also plans to discuss commercial readiness and launch strategy for its three upcoming launches at its Commercial Day on October 8, 2026. The next financial read will require the omitted income-statement and cash-flow data to assess how product revenue and the post-quarter financing translate into operating leverage and funding duration.
Management, verbatim
I'm excited by the growing body of evidence continuing to demonstrate Attruby is the drug of choice for all ATTR-CM patients, and particularly for those who are treatment-naïve, including the first-ever demonstration of early, sustained kidney-protective effects in ATTR-CM alongside the cardiac benefit we've established.
Neil Kumar, Ph.D., Co-Founder and CEO of BridgeBio
We continue to see strong growth this quarter for Attruby with our first-line share climbing again.
Matt Outten, Chief Commercial Officer of BridgeBio
Not in the filing
stated, not guessed- GAAP gross profit and gross margin
- Non-GAAP gross profit and gross margin
- GAAP operating income or loss
- Non-GAAP operating income or loss
- GAAP net income or loss
- Non-GAAP net income or loss
- GAAP earnings or loss per share
- Non-GAAP earnings or loss per share
- Operating cash flow
- Free cash flow
- Operating expenses
- Debt balance
- Share repurchases
- Dividends
- Prior-year comparisons for reported revenue metrics
- Prior-quarter comparisons for reported revenue metrics
- Formal financial guidance for revenue, gross margin, operating expenses, or tax rate
- Previous-quarter outlook for comparison
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This SEC Form 8-K (Item 2.02) reports BridgeBio’s Q2 2026 financial results and provides corporate and pipeline updates, including regulatory review status for three upcoming launches.
Ticker impact
BridgeBio reports Q2 2026 results and says all three pipeline NDAs are now in FDA review, with Priority Review PDUFA dates set for BBP-418 and encaleret.
Likely positive bias as traders focus on the first PDUFA date (Nov 27, 2026) and the balance-sheet runway supporting three launches.
The filing is an SEC 8-K with fresh, time-stamped facts: Q2 revenue and cash balance, plus acceptance of two Priority Review NDAs and submission of the third, each with specific PDUFA timing.
Market effects
Reinforces investor focus on ATTR and rare-disease oral pipeline execution, potentially supporting sentiment toward specialty biopharma with near-term FDA review timelines.
Limited direct regional spillover beyond US biotech sentiment.
Moderate, as the company references multi-region approvals for acoramidis and FDA review milestones that can influence global rare-disease peers’ expectations.
Counterpoint
Despite Priority Review acceptance, FDA outcomes remain uncertain; traders may fade the news if they believe the clinical differentiation is already priced or if label/commercial constraints emerge.
Key entities
- companyBridgeBio Pharma, Inc.
Commercial-stage biopharmaceutical company; subject of the SEC 8-K with Q2 results and FDA review milestones for three pipeline programs.
- productAttruby (acoramidis)
TTR stabilizer for ATTR-CM; company highlights U.S. net product revenue growth and new post-hoc and real-world evidence.
- pipeline_programBBP-418
NDA for LGMD2I/R9 accepted with Priority Review; PDUFA set for November 27, 2026.
- pipeline_programencaleret
NDA for ADH1 accepted with Priority Review; PDUFA set for May 8, 2027.
- pipeline_programoral infigratinib
NDA submitted for achondroplasia; U.S. launch expected mid-2027 per company.
